NEUROPSYCHOLOGICAL DISORDERS IN WOMEN WITH METABOLIC SYNDROME: DYNAMICS AND A MULTIDISCIPLINARY APPROACH

Authors

  • M.S.Khaknazarova Tashkent State Medical University, Termez Branch, Uzbekistan Author
  • R.J.Matmurodov Tashkent State Medical University, Termez Branch, Uzbekistan Author

Keywords:

Keywords: metabolic syndrome, women, neuropsychological disorders, cognitive impairment, anxiety, depression, sleep disturbances, LDLR gene, multidisciplinary approach, quality of life.

Abstract

Metabolic syndrome (MS) is one of the most important contemporary medical and social problems due to its increasing prevalence, multisystemic nature, and association with cardiovascular, cerebrovascular, endocrine, and neuropsychological complications. Although the metabolic and cardiovascular consequences of MS have been extensively studied, neuropsychological manifestations, particularly their dynamics in women, remain insufficiently investigated. Women with MS may develop cognitive impairment, anxiety, depressive symptoms, sleep disturbances, emotional instability, autonomic dysfunction, and reduced quality of life. These manifestations may negatively affect treatment adherence, social functioning, rehabilitation potential, and long-term prognosis.The aim of this study is to comprehensively evaluate the dynamics of neuropsychological disorders in women with metabolic syndrome and to develop an appropriate multidisciplinary approach for their early detection, correction, and rehabilitation. The planned study will include more than 100 women with metabolic syndrome receiving outpatient or inpatient medical care. A control group consisting of age-matched women without metabolic syndrome will also be examined. Clinical-neurological, biochemical, neuropsychological, genetic, and statistical methods will be applied. Cognitive functions will be assessed using the Montreal Cognitive Assessment (MoCA) and Addenbrooke’s Cognitive Examination III (ACE-III). Anxiety and depressive symptoms will be evaluated using the Hospital Anxiety and Depression Scale (HADS) and the Depression Anxiety and Stress Scale (DASS-21). Health-related quality of life will be assessed using the EQ-5D questionnaire. Biochemical investigations will include glucose, glycated hemoglobin, lipid profile, insulin, homocysteine, and C-reactive protein. Genetic analysis will focus on the LDLR gene and its possible association with neuropsychological manifestations.

 

Downloads

Published

2026-10-15